Cumberland Pharmaceuticals (NASDAQ:CPIX) & Quoin Pharmaceuticals (NASDAQ:QNRX) Financial Review

Quoin Pharmaceuticals (NASDAQ:QNRX) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Quoin Pharmaceuticals and Cumberland Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1	0	1	0	2.00
Cumberland Pharmaceuticals	1	0	0	0	1.00

Risk & Volatility

Quoin Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.

Institutional & Insider Ownership

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Quoin Pharmaceuticals and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

Valuation & Earnings

This table compares Quoin Pharmaceuticals and Cumberland Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81 million	($29.56)	-0.15
Cumberland Pharmaceuticals	$44.52 million	2.30	-$2.84 million	($0.49)	-13.96

Cumberland Pharmaceuticals has higher revenue and earnings than Quoin Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Cumberland Pharmaceuticals beats Quoin Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.